BDD excels at modified release drug delivery, whilst accelerating your molecule to market.
Through applying BDD’s tablet modified release platform, OralogiK, BDD can give your active a bespoke delivery to the target site to suit several unique patient profiles.
To accelerate the clinical development process of your drug, BDD offers adaptive clinical trials, BDD Swift. BDD Swift incorporates formulation development, GMP manufacture and clinical testing in man for multiple formulations in parallel screening; all of which are continuously improved after each test until you have one lead formulation. Giving you crucial data to confidently take you to commercial success.
View your drug deposition in real-time, through gamma scintigraphy. Creating further data to be compared with PK results to further guide your decision making to success.